The Role of Palliative Care in Lung Cancer
Summary of Key Points • The best palliative outcomes are obtained when palliative care is involved early in advanced lung cancer. • Integration of palliative care early in the advanced…
ONCOLOGY
Malignant Mesothelioma
Summary of Key Points • Development of malignant mesothelioma is usually associated with asbestos exposure. • The most common genetic alterations in mesothelioma are deletion of CDKN2A/ARF , inactivation of…
Clinical Trial Methodology in Lung Cancer: Study Design and End-Point Considerations
Summary of Key Points • Lung cancer is increasingly understood at the molecular level; N-of-1 trials are becoming more relevant with the use of biomarker assessment and targeted therapies. •…
How to Promote and Organize Clinical Research in Lung Cancer
Summary of Key Points • Despite two decades of progress, the prognosis for patients with lung cancer remains poor. Therefore forming new hypotheses and conducting clinical trials to investigate this…
The Role of Advocacy Groups in Lung Cancer
Summary of Key Points † Deceased. • To describe the functions of advocacy. • To describe how lung cancer advocacy groups accomplish their goals. • To describe how they can…
The Role of Health Services Research in Improving the Outcomes for Patients With Lung Cancer
Summary of Key Points • Health services research aims to improve the outcomes to treatment for lung cancer by optimizing the accessibility, quality, and efficiency of treatment programs. • Achieving…
Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer
Summary of Key Points • Surgery remains the most effective curative approach for early-stage (IA–IIB) NSCLC. Selected cases with clinical stage IIIA disease equally benefit from radical resection. • Stereotactic…
Management of Toxicities of Targeted Therapies
Summary of Key Points • Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, C-ros oncogene 1 (ROS1), ret proto-oncogene (RET) tyrosine kinase inhibitors (TKIs), several antiangiogenesis agents, and…
Treatment of Extensive-Stage Small Cell Lung Cancer
Summary of Key Points • Performance status is universally recognized as an independent prognostic factor and typically correlates with the extent of tumor burden. • As first-line therapy, platinum agent…
New Targets for Therapy in Lung Cancer
Summary of Key Points • Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. • Despite…
